Niagen Bioscience (NAGE) Depreciation & Amortization (CF) (2016 - 2017)

Niagen Bioscience (NAGE) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $116000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 26.58% year-over-year to $116000.0; the TTM figure through Mar 2026 stood at $570000.0 (down 11.35% YoY), while the FY2025 annual figure was $612000.0, down 7.69% from the prior year.
• Depreciation & Amortization (CF) retreated to $116000.0 in Q1 2026 per NAGE's latest filing, from $139000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $235000.0 in Q3 2022 and bottomed at $116000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $184117.6 across 5 years, with a median of $177000.0 in 2023.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) climbed 13.43% — and 2024, when it decreased 29.61%.
• Niagen Bioscience's Depreciation & Amortization (CF) stood at $221000.0 in 2022, then decreased by 19.91% to $177000.0 in 2023, then decreased by 14.69% to $151000.0 in 2024, then retreated by 7.95% to $139000.0 in 2025, then declined by 16.55% to $116000.0 in 2026.
• Business Quant data shows NAGE's Depreciation & Amortization (CF) at $116000.0 in Q1 2026, $139000.0 in Q4 2025, and $157000.0 in Q3 2025.